Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novogen of Australia Reports Favorable Trial For Pancreatic Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

Australia's Novogen said it received favorable reports from trials on its triphendiol for treating pancreatic cancer. The drug was tried in combination with Eli Lilly's Gemzar (gemcitabine hydrochloride). The Sydney-based company recently announced positive results for its promensil product for maintaining ovarian cancer remission in addition to its use for treating menopausal symptoms. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts